Literature DB >> 25857185

[The study of human pregnancy specific β1-glycoprotein immunomodulating effects].

S A Zamorina, M B Raev.   

Abstract

Effect of human Pregnancy specific β1-glycoprotein (PSG) in physiological concentrations was analyzed against the expression of natural killer (NK)-, T-cells with natural killer functions (N KT-) and T-regulatory lymphocyte (Treg) markers, as well as on the activity of monocyte indolamine-2,3-dioxygenase (IDO) and lymphocyte apoptosis in vitro. It was revealed that PSG in high concentration (100 μg/mL) suppressed the CD16/56 expression by NK-cells, while inhibiting the cytolytic activity of these cells. Meanwhile, PSG in low concentrations (1 and 10 μg/mL) enhanced the CD16/56 expression by NKT-cells that was related to cytokine-producing activity. It was found that PSG increased the number of adaptive Tregs in culture (CD4+FOXP3+ and CD4+CD25(bright)FOXP3+). In addition, PSG promoted the IDO activity in peripheral monocytes, while further potentiating the Treg generation. In general, PSG rendered anti-apoptotic action on lymphocytes. Therefore, indicated effects can determine the PSG contribution to the development of immune tolerance in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25857185

Source DB:  PubMed          Journal:  Fiziol Cheloveka        ISSN: 0131-1646


  2 in total

1.  Effect of pregnancy-specific β1-glycoprotein on indoleamine-2,3-dioxygenase activity in human monocytes.

Authors:  S A Zamorina; V P Timganova; M S Bochkova; P V Khramtsov; M B Raev
Journal:  Dokl Biol Sci       Date:  2016-09-07

Review 2.  Molecules and Prostaglandins Related to Embryo Tolerance.

Authors:  Gabriel Mayoral Andrade; Gabriela Vásquez Martínez; Laura Pérez-Campos Mayoral; María Teresa Hernández-Huerta; Edgar Zenteno; Eduardo Pérez-Campos Mayoral; Margarito Martínez Cruz; Ruth Martínez Cruz; Carlos Alberto Matias-Cervantes; Noemi Meraz Cruz; Carlos Romero Díaz; Eli Cruz-Parada; Eduardo Pérez-Campos
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.